Dr. Plimack Discusses Trials Investigating Apalutamide, Enzalutamide in M0 CRPC
February 9th 2018Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses 2 studies reported at the 2018 Genitourinary Cancers Symposium in patients with nonmetastatic M0 castration-resistant prostate cancer (CRPC).
Read More
Dr. Plimack on Strategies for Developing Cure for Locally Advanced Urothelial Carcinoma
September 28th 2017Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses strategies for developing cures for patients with locally advanced urothelial carcinoma.
Read More
Dr. Plimack on the Challenges With Available Immunotherapies for Bladder Cancer
August 15th 2017Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, shares the challenges with the FDA-approved immunotherapy agents for the treatment of patients with bladder cancer.
Read More
Dr. Plimack on Frontline Pembrolizumab for Urothelial Carcinoma
July 7th 2017Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the KEYNOTE-052 trial investigating pembrolizumab (Keytruda) in the frontline setting for patients with urothelial carcinoma.
Read More
Dr. Plimack on KEYNOTE-045 Trial for Pembrolizumab in Urothelial Carcinoma
June 22nd 2017Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the updated findings of the KEYNOTE-045 trial of pembrolizumab (Keytruda) in urothelial carcinoma.
Read More
Dr. Plimack on Significance of CheckMate-025 Trial in RCC
November 5th 2016Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses updated findings from the CheckMate-025 trial, which compared the efficacy of nivolumab (Opdivo) with everolimus (Afinitor) in patients with renal cell carcinoma.
Read More